Relationship of Marrow Radiation Dose and Timing of Engraftment for Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

医学 放射免疫疗法 骨髓 髓系白血病 核医学 随机对照试验 白血病 内科学 造血干细胞移植 肿瘤科 耐火材料(行星科学) 放射治疗 髓样 移植 免疫学 单克隆抗体 抗体 物理 天体生物学
作者
Susan Passalaqua,Mona Natwa,Ming-Kai Chen,Robert H. Wagner,Wendell Yap,Landis K. Griffeth,Gregory A. Wiseman,Joyce Mhlanga,Richard L. Wahl,Norbert Avril,Robert S. Hellman,Dominick Lamonica,Manuela Matesan,Beth Chasen,Neil J. Hansen,Eugene Leung,Joseph R. Osborne,Jennifer Peterson,Yusuf Menda,Dinko Franceschi,Qing Liang,Vijay Reddy,Mark S. Berger,Neeta Pandit‐Taskar
摘要

82 Background: Patients ≥ 55 years of age with high-risk acute myeloid leukemia (AML) may benefit from an allogeneic hematopoietic stem cell transplantation (HSCT), which is often the only potentially curative therapy available. However, complete remission (CR) is usually a prerequisite for most centers to perform HSCT, as CR predicts an optimal outcome. Many older patients with relapsed/refractory (R/R) AML do not receive HSCT, as they do not achieve the required CR. Additionally, many are unable to tolerate the myeloablative conditioning required for eradication of disease. While the reduced intensity conditioning is better tolerated, it often exhibits high rates of relapse. SIERRA trial is a prospective, randomized, phase 3 trial for older patients with R/R AML to address this unmet need. Iomab-B (131I labeled apamistamab) targets CD45, which is highly expressed in leukemia cells. We hypothesized that the targeted delivery of therapeutic Iomab-B with an imaging-based dosimetry enables successful engraftment despite active disease in the marrow.Methods: Eligible patients with active R/R AML, adequate organ function, and related/unrelated 8/8 HLA-matched donors were randomized (1:1) to the Iomab-B or Conventional Care (CC) arm. Patients randomized to Iomab-B received a low dose of Iomab-B, followed by 3 sequential gamma camera images (Fig 1) to determine the personalized therapeutic dose that would deliver maximal radiation to the marrow while limiting the liver dose to 24 Gy. Dosimetry was performed using serial imaging data and Olinda program (V2.1, Hermes Medical). Following a therapeutic infusion of Iomab-B and a non-myeloablative conditioning backbone of fludarabine (30 mg/m2 x 3) and 2 Gy Total Body Irradiation, HSCT was performed 12-14 days later. Each patient on the CC arm received the investigator’s choice of non-radioactive salvage therapy and could proceed to HSCT if they achieved CR. If no CR, the study allowed patients to cross over and receive Iomab-B-based conditioning followed by allogeneic HSCT. Patient age, donor type, bone marrow cellularity, blast percentage, type of donor, stem cell dose, administered Iomab-B activity (mCi), and radiation dose to marrow (Gy), were analyzed for a relationship to days to engraftment among each group. Results: Preliminary data were available from 113 patients (Table 1). 56 patients were randomized to Iomab-B for which 49 patients received allogeneic transplant. In the CC arm, 82% (47/57) of patients failed salvage therapy. 30 of the 47 (64%) CC patients crossed over and received Iomab-B followed by allogeneic HSCT. Median time to neutrophil and platelet engraftment were 14 days (range 9-22) and 18 days (range 4-39), respectively, in Iomab-B group, with 89% of evaluable patients achieving full donor chimerism (> 95% by day 100). All patients who received Iomab-B treatment achieved engraftment, including the Iomab-B group and the cross-over patients. Neither the radiation dose delivered to marrow (median 14.7 Gy; range 4.6-32 Gy) nor the administered activity (median 646 mCi; range 354-1027 mCi) showed correlation with the time to either neutrophil (p = 0.525) or platelet engraftment (p = 0.952). Regression analyses, considering all the variables individually, did not indicate a statistically significant correlation (p > 0.1) between days to engraftment and marrow dose. These results were consistent for the cross-over group. Furthermore, the marrow radiation dose did not show a significant correlation with % chimerism at day 28 in patients on the Iomab-B arm or in cross-over patients. Conclusion: No significant relationship between total administered activity or radiation dose to marrow with the speed of engraftment was found, indicating the dosimetry estimates for ablative doses appear to be adequate and successful in ablation, despite a heavy leukemia burden prior to HSCT.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
lingchuan发布了新的文献求助10
刚刚
1秒前
kiuikiu发布了新的文献求助10
1秒前
情怀应助cc采纳,获得10
1秒前
苏打发布了新的文献求助10
1秒前
weilai完成签到,获得积分20
1秒前
贝果小脑袋完成签到,获得积分10
2秒前
木偶人完成签到,获得积分10
2秒前
Aimedar发布了新的文献求助10
2秒前
guohuameike发布了新的文献求助10
2秒前
3秒前
橘子发布了新的文献求助10
3秒前
3秒前
4秒前
4秒前
wjx发布了新的文献求助10
5秒前
5秒前
6秒前
6秒前
iNk应助你怎么睡得着觉采纳,获得20
6秒前
橙子完成签到,获得积分20
6秒前
6秒前
雪白的山雁完成签到,获得积分10
7秒前
ZZ发布了新的文献求助10
7秒前
ks完成签到,获得积分10
8秒前
8秒前
Grace发布了新的文献求助10
9秒前
小小猪发布了新的文献求助10
10秒前
STOOd发布了新的文献求助10
10秒前
Goodluck发布了新的文献求助10
10秒前
Sarah完成签到,获得积分10
11秒前
11秒前
Z可发布了新的文献求助10
11秒前
慕青应助wawaeryu采纳,获得50
12秒前
华仔应助神奇小鹿采纳,获得10
13秒前
fanfan发布了新的文献求助10
14秒前
随意完成签到,获得积分10
14秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974882
求助须知:如何正确求助?哪些是违规求助? 3519431
关于积分的说明 11198315
捐赠科研通 3255698
什么是DOI,文献DOI怎么找? 1797904
邀请新用户注册赠送积分活动 877237
科研通“疑难数据库(出版商)”最低求助积分说明 806219